The impact of age, sex and body mass index on interstitial glucose levels as measured via continuous glucose monitoring (CGM) during exercise in the healthy population is largely unexplored. We conducted a multivariable generalized estimating equation (GEE) analysis on CGM data (Dexcom G6, 10 days) collected from 119 healthy exercising individuals using CGM with the following specified covariates: age; sex; BMI; exercise type and duration. Females had lower postexercise glycemia as compared with males (92 ± 18 vs. 100 ± 20 mg/dL, p = 0.04) and a greater change in glycemia during exercise from pre- to postexercise (p = 0.001) or from pre-exercise to glucose nadir during exercise (p = 0.009). Younger individuals (i.e., <20 yrs) had higher glucose during exercise as compared with all other age groups (all p < 0.05) and less CGM data in the hypoglycemic range (<70 mg/dL) as compared with those aged 20–39 yrs (p < 0.05). Those who were underweight, based on body mass index (BMI: 140 mg/dL) (p = 0.03) ranges. In summary, various factors such as age, sex and exercise type appear to have subtle but potentially important influence on CGM measurements during exercise in healthy individuals.
Background: Elevated levels of somatostatin blunt glucagon counterregulation during hypoglycemia in type 1 diabetes (T1D) and this can be improved using somatostatin receptor 2 (SSTR2) antagonists. Hypoglycemia also occurs in late-stage type 2 diabetes (T2D), particularly when insulin therapy is initiated, but the utility of SSTR2 antagonists in ameliorating hypoglycemia in this disease state is unknown. We examined the efficacy of a single-dose of SSTR2 antagonists in a rodent model of T2D.Methods: High-fat fed (HFF), low dose streptozotocin (STZ, 35 mg/kg)-induced T2D and HFF only, nondiabetic (controls-no STZ) rats were treated with the SSTR2 antagonists ZT-01/PRL-2903 or vehicle (n = 9–11/group) 60 min before an insulin tolerance test (ITT; 2–12 U/kg insulin aspart) or an oral glucose tolerance test (OGTT; 2 g/kg glucose via oral gavage) on separate days.Results: This rodent model of T2D is characterized by higher baseline glucose and HbA1c levels relative to HFF controls. T2D rats also had lower c-peptide levels at baseline and a blunted glucagon counterregulatory response to hypoglycemia when subjected to the ITT. SSTR2 antagonists increased the glucagon response and reduced incidence of hypoglycemia, which was more pronounced with ZT-01 than PRL-2903. ZT-01 treatment in the T2D rats increased glucagon levels above the control response within 60 min of dosing, and values remained elevated during the ITT (glucagon Cmax: 156 ± 50 vs. 77 ± 46 pg/mL, p < 0.01). Hypoglycemia incidence was attenuated with ZT-01 vs. controls (63% vs. 100%) and average time to hypoglycemia onset was also delayed (103.1 ± 24.6 vs. 66.1 ± 23.6 min, p < 0.05). ZT-01 administration at the OGTT onset increased the glucagon response without exacerbating hyperglycemia (2877 ± 806 vs. 2982 ± 781), potentially due to the corresponding increase in c-peptide levels (6251 ± 5463 vs. 14008 ± 5495, p = 0.013).Conclusion: Treatment with SSTR2 antagonists increases glucagon responses in a rat model of T2D and results in less hypoglycemia exposure. Future studies are required to determine the best dosing periods for chronic SSTR2 antagonism treatment in T2D.
In diabetes, glucagon is typically oversecreted during hyperglycemia but undersecreted during hypoglycemia. Administration of a somatostatin receptor antagonist (SSTR2a) increases glucagon counterregulation during hypoglycemia in rodent models of type 1 diabetes (T1D) but less is known about its effect on glucagon in type 2 diabetes (T2D). Using a rodent model of insulin-requiring diabetes, we evaluated the effects of daily SSTR2a administration with insulin dosing (study A: 8 days) and repeated exposures to hypoglycemia (study B: 4× over 11 days) on glucagon and glycemia. In study A, 8 days of SSTR2a treatment at 3.0 mg/kg transiently increased glucagon levels after dosing but did not significantly affect the glycemic response to basal or bolus insulin. In study B, with daily low-dose SSTR2a treatment (0.3 mg/kg/d), the glucagon counterregulatory response to insulin-induced hypoglycemia increased while time to hypoglycemic onset was delayed on challenge days 1 and 2. SSTR2a treatment did not affect food intake, body mass, or C-peptide levels, but was associated with a lower glycated hemoglobin A1c level at the end of the study relative to controls (4.3 ± 0.9 vs 5.3 ± 0.8%; P < .05). In summary, in a rat model of insulin-treated T2D, daily SSTR2a administration increased glucagon counterregulation to hypoglycemia without worsening overall insulin sensitivity or glycemic control.
Glycemic control may differ throughout the menstrual cycle, with increased incidence of hyperglycemia in the luteal phase. However, it is unclear if glycemic differences exist in the follicular vs. luteal phase during prolonged fasted exercise in T1D. The aim of this study was to determine if the early follicular vs. luteal phase impacts blood glucose levels during and post-exercise. Females with T1D (n = 7, age 28±6 years, A1c 6.9±0.6%) completed two 2-hr aerobic exercise sessions (∼45% VO2peak), during the luteal (days 18-24) and early-follicular phases (days 1-6) of menstruation. Carbohydrate (CHO) intake (0.3g/kg/hr) occurred every 30-min if glucose was between 72-180 mg/dL. No differences existed between the two phases for starting glucose, changes in glucose, CHO consumption and CHO oxidation during exercise (Table). Baseline glucagon was elevated in the luteal (28±25pg/mL) vs. follicular phase (13±12pg/mL; P180 mg/dL) was greater in the luteal (59±44%) vs. follicular phase (21±30%; P<0.05). Overall, glycemic responses during prolonged fasting exercise are similar between luteal and follicular phases in women with T1D, as are CHO intake needs. However, after exercise in the luteal phase, glycemia tends to be elevated and appears to contribute to greater time in hyperglycemia. Disclosure S.M. McGaugh: None. D. Zaharieva: Speaker’s Bureau; Self; Ascensia Diabetes Care, Insulet Corporation, Medtronic. R. Pooni: None. N.C. D’Souza: None. J.E. Yardley: Research Support; Self; Abbott, Dexcom, Inc., LifeScan Canada. Speaker’s Bureau; Self; Dexcom, Inc. M. Riddell: Advisory Panel; Self; Zucara Therapeutics Inc. Consultant; Self; Lilly Diabetes. Research Support; Self; Dexcom, Inc., Insulet Corporation. Speaker’s Bureau; Self; Medtronic, Novo Nordisk A/S.
Introduction: Administration of a somatostatin receptor 2 antagonist (SSTR2a) increases glucagon responsiveness to hypoglycaemia in insulin‐treated type 2 diabetes (T2D), but the durability of this effect and the impact of repeated SSTR2a dosing on overall glycaemia in T2D are unclear. This study evaluated the effects of daily SSTR2a administration on glucagon counterregulation and overall glycaemia in a male rat model of T2D. Methods: T2D was induced in male Sprague–Dawley rats using high‐fat feeding and streptozotocin (35 mg/kg) (day 0). After a 7‐day insulin maintenance period, T2D and control rats were administered a single dose of SSTR2a (ZT‐01, 3 mg/kg) or vehicle ( n = 7–8 per group) prior to a hypoglycaemic challenge with an insulin overdose (day 8). After a one‐week washout period, T2D and control rats were administered drug or vehicle for 8 days, with a second hypoglycaemic challenge performed on the last day. Results: Glucagon counterregulation to both hypoglycaemic exposures increased with SSTR2a in T2D and controls (all p < 0.05). Dosed without hypoglycaemia, SSTR2a induced a transient rise in glucagon, c‐peptide, and glucose levels in both healthy and T2D rats, but food intake and body weight were unaffected. T2D rats on SSTR2a (days 8–22) had reduced daily insulin needs without significantly affecting blood glucose levels. Conclusion: In this male rat model of T2D, repeat dosing of SSTR2a increases glucagon counterregulation without worsening glycemia.